Chinese Registry of Rheumatoid Arthritis (CREDIT) VI: Temporal Trends in Patients With Early Rheumatoid Arthritis and Moderate‐To‐Severe Disease Activity ‐ A Multicenter Cohort Study of Treatment Strategies and Outcomes
- 17 January 2025
- journal article
- research article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (1) , e70066
Abstract
Aim: The continuous update of international guidelines and enhanced availability of biological disease‐modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have made a significant impact on the diagnosis and treatment of early rheumatoid arthritis (ERA). This study aims to systematically evaluate the current treatment strategies and outcomes within a large‐scale cohort of patients with ERA. Methods: Data from the Chinese Registry of Rheumatoid Arthritis (CREDIT), a large multicenter Chinese registry of RA, were collected to analyze temporal trends in clinical profiles, therapeutic strategies, and treatment outcomes among patients with ERA. Results: From November 2016 to October 2023, A total of 2722 patients with follow‐up information for 6 months were included. The use of methotrexate (MTX) increased annually and has become the predominant DMARD as the initial treatment. Following initial therapy, 1059 (38.9%) patients achieved the therapeutic target of low disease activity and remission. Age ≥ 50 years (adjusted OR 0.70 [95% CI 0.59–0.83]; p < 0.001), high baseline disease activity (adjusted OR 0.48 [95% CI 0.41–0.57]; p < 0.001), csDMARD monotherapy other than MTX (adjusted OR 0.55 [95% CI 0.41–0.73]; p < 0.001), and the use of b/tsDMARDs without a csDMARD combination (adjusted OR 0.57 [95% CI 0.36–0.87]; p = 0.011) were associated with lower target attainment rates. For patients who did not achieve the treatment target after initial therapy, the use of b/tsDMARDs increased after 2020, although the extent of therapeutic escalation remained suboptimal. Conclusion: Treatment of patients with ERA in China has become more standardized. Adherence to guideline‐directed therapeutic regimens has emerged as a significant determinant of therapeutic target achievement. The increased prevalence of b/tsDMARDs would benefit more patients in ameliorating the disease.Keywords
This publication has 34 references indexed in Scilit:
- Choice of and response to treatment in patients with early-diagnosed rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J)Journal of Orthopaedic Science, 2023
- Rheumatoid Arthritis — Common Origins, Divergent MechanismsNew England Journal of Medicine, 2023
- A Bridge Too Far? Real‐World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis CohortACR Open Rheumatology, 2021
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis & Rheumatology, 2021
- Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled TrialArthritis & Rheumatology, 2020
- Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohortClinical Rheumatology, 2019
- Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective CohortArthritis Care & Research, 2019
- Diagnosis and Management of Rheumatoid ArthritisJAMA, 2018
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Segmented regression analysis of interrupted time series studies in medication use researchJournal of Clinical Pharmacy and Therapeutics, 2002